Zhongzhi Pharmaceutical Holdings Limited
HKSE: 3737.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Zhi Tian Lai
- Employees
- 2,577
- Headquarters
- Zhongshan, China
- IPO year
- 2015
- Market cap
- HK$691.9M
- Website
- https://www.zeus.cn
Loading 3737…
Loading profile data…Frequently asked questions about 3737
What does Zhongzhi Pharmaceutical Holdings Limited (3737.HK) do?
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmaceutical Manufacturing, Operation of Chain Pharmacies, and Operation of On-Line Pharmacies. It provid...
Where does 3737.HK trade?
Zhongzhi Pharmaceutical Holdings Limited (3737.HK) trades on the Hong Kong Stock Exchange.
What sector is 3737.HK in?
Zhongzhi Pharmaceutical Holdings Limited (3737.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Zhongzhi Pharmaceutical Holdings Limited?
Zhi Tian Lai is the chief executive officer of Zhongzhi Pharmaceutical Holdings Limited (3737.HK).
Where is Zhongzhi Pharmaceutical Holdings Limited headquartered?
Zhongzhi Pharmaceutical Holdings Limited is headquartered in China.
Does 3737.HK pay a dividend?
Yes — Zhongzhi Pharmaceutical Holdings Limited (3737.HK) paid a trailing twelve-month dividend of HKD 0.05 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 3737.HK go public?
Zhongzhi Pharmaceutical Holdings Limited (3737.HK) completed its initial public offering in 2015.